Skip to main content
. 2014 Mar 6;36(1):51–59. doi: 10.1093/eurheartj/ehu095

Figure 1.

Figure 1

SRT3025 confers atheroprotection, reduces plasma cholesterol and systemic inflammation in Apoe−/− mice. Eight-week-old Apoe−/− mice were fed a high-cholesterol diet (1.25% w/w) supplemented with the Sirt1 activator SRT3025 (n = 9) or placebo (n = 9) for 12 weeks. Representative micrographs (left) and quantifications (right) of thoraco-abdominal aortae en face (A) and of aortic root cross sections (B–D) stained with ORO or immunohistochemically for macrophages (Cd68) or Vcam-1; (E) cholesterol distribution in the different lipoprotein subfractions separated by gel filtration chromatography; (F) Plasma total cholesterol, LDL-, and VLDL-cholesterol concentrations; (G) Plasma levels of Mcp-1 and Il-6. Scale bars in photomicrographs: 1 mm (A) and 500 μm (B–D). HCD, high-cholesterol diet; AU, arbitrary units; LDL, low-density lipoprotein; ORO, oil-red O; VLDL, very low-density lipoprotein; Vcam-1, vascular cell adhesion molecule 1; Mcp-1, monocyte chemoattractant protein 1; Il-6, interleukin 6.